

1 Introduction of Dengue Virus Serotype 3 in the Afar Region, Ethiopia

2
3 Feleke Mekonnen, Bilal A. Khan, Endalkachew Nibret, Abaineh Munshea, Daniel
4 Tsega, Demeke Endalamaw, Senait Tadesse, Gizachew Yismaw, Damtie Lankir, Jemal Ali,
5 Mariana Ulinici, Emanuele Orsini, Ursa Susnjar, Tea Carletti, Danilo Licastro, Molalegne
6 Bitew, Marta Giovanetti, Alessandro Marcello
7

8 Author affiliations: Bahir Dar University, Bahir Dar, Ethiopia (F. Mekonnen, E. Nibret, A.
9 Munshea, S. Tadesse); International Center for Genetic Engineering and Biotechnology
10 (ICGEB), Trieste, Italy (B. A. Khan, M. Ulinici, E. Orsini, U. Susnjar, T. Carletti, A. Marcello);
11 Dow University of Health Sciences, Karachi, Pakistan (B.A. Khan); Nicolae Testemitanu
12 Uniresity of Medicine and Pharmacy, Republic of Moldova (M.Ulinici); Ethiopian Public
13 Health Institute (EPHI), Addis Ababa, Ethiopia (D. Tsega); Amhara Public Health Institute
14 (APHI), Bahir Dar, Ethiopia (D. Endalamaw, G. Yismaw, D. Lankir); J.Ali (Afar Public
15 Health and Research Institute); Bio and Emerging Technology Institute (BETiN), Addis
16 Ababa, Ethiopia (M. Bitew); Department of Sciences and Technologies for Sustainable
17 Development and One Health, Universita Campus Bio-Medico di Roma, Italy (M. Giovanetti).
18 Oswaldo Cruz Institute, Rio de Janeiro, Brazil (M. Giovanetti); AREA Science Park, Trieste,
19 Italy (D.Licastro, A. Marcello).

20 Abstract

21 The genetic analysis of the Dengue virus circulating in Ethiopia's Afar region, in 2023,
22 identified three distinct introductions with spatiotemporal clustering linked to genomes from
23 Asia and Italy. These findings are crucial for enhancing prevention and control strategies,
24 reinforcing the necessity to provide sustainable tools for genomic epidemiology in Africa.

25 Introduction


26 Ethiopia has been experiencing annual dengue outbreaks since the first cases were reported in
27 Dire Dawa in 2013 (1). Subsequent outbreaks occurred in the Eastern and Southern districts,
28 including Godey town and Arbaminch, in 2020 (2). In 2019 an outbreak occurred in the
29 Gawane District of the Afar Region in Noth-Eastern Ethiopia (3). Dengue serotypes 1 and 2
30 (DENV-1 and DENV-2) have been reported in the country (4,5), while dengue virus serotype
31 3 (DENV-3) was detected only recently in the Afar Region (6). Despite the increasing number
32 of cases, much is still unknown about the genomic diversity and evolution of DENV lineages
33 currently circulating in the country. To address this gap, a cross-sectional study was conducted
34 from June to October 2023 on 384 acute febrile (AFI) patients attending three healthcare
35 facilities in the Afar Region: Logia, Mille and Gewane. The study was conducted within
36 EXPANDIA (Expanding Diagnostics and Surveillance in Africa), a project implemented by
37 the International Centre for Genetic Engineering and Biotechnology (ICGEB).

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

36 The Study

37 Patients presenting at Logia, Mille, and Gewane healthcare facilities in the Afar Region
38 exhibiting symptoms typical of dengue were included in this study. These symptoms comprised
39 an acute onset of high fever persisting for 2-7 days, severe joint and muscle pain, headache,
40 retro-orbital pain, rash, nausea/vomiting, and unusual bleeding, or bruising. We included 384
41 patients who visited these facilities between June and October 2023. The Regional Public
42 Health Research Ethics Review Committee, Ethiopia, approved the study (Ref.
43 NoH/R/T/T/D/07/39). Sociodemographic and clinical information, along with other relevant
44 data, was gathered using a structured questionnaire (**Appendix 1 Table 1&2**).

45 Malaria infection was excluded using a smear test on whole blood. Serum was obtained from
46 venous puncture and tested on-site using the Wondfo One Step Dengue IgG/IgM test
47 (Guangzhou Wondfo Biotech Co., Ltd., China). Serum samples that tested positive for DENV-
48 specific IgM (32.8%, 126/384) and/or IgG (36.2%, 139/384) were transported at -20 °C to
49 Addis Ababa (APHI and BETiN) and to ICGEB. Viral RNA purification from serum was
50 performed using the QIAamp Viral RNA Mini Kit (Qiagen, Germany), and DENV RNA was
51 detected using the Luna Universal Probe One-Step RT-qPCR Kit (NEB) using in-house pan-
52 Dengue primers and probe. Positive samples were assigned to the DENV-3 serotype by
53 amplifying the C-prM region, as previously described (7), followed by Sanger sequencing and
54 data analysis using the Genome Detective DENV typing tool (8). Samples (n=7) with a cycle
55 threshold (Ct) value of ≤ 32 and available epidemiological metadata - such as the date of
56 symptom onset, date of sample collection, sex, age, municipality of residence, symptoms, and
57 disease classification, were subjected to a nanopore whole genome sequencing using a set of
58 tiled primers (9) following previously described protocols with slight modifications (10). For
59 amplification of DENV-3 genome, 30 primers were used (7) to cover the almost entire coding
60 sequence (CDS) of the DENV-3 genome (positions 132 to 10139) in 800-900 bp amplicons
61 (**Appendix 2 primer list & protocol**). We reconstructed phylogenetic trees to explore
62 relationships between sequenced genomes from Ethiopia (n=7) and other global regions
63 (n=351) (**Appendix 3**).



64

65 **Figure 1. Dynamics of DENV-3 in Ethiopia.** a) The percentage of DENV genome sequenced plotted against RT-qPCR Ct value for each
 66 sample (n = 7). Each circle represents a sequence recovered from an infected individual in Ethiopia and is coloured by sampling location; b)
 67 Map of Ethiopia showing the sampling locations of new DENV-3 genome sequences by region and district. The size of the circles represents
 68 the number of new genomes generated in each district; c) Time-stamped Maximum Likelihood tree including the novel DENV-3 sequences

69 (n=7) generated in this study, along with n=351 reference strains belonging to DENV-3 genotype III sampled worldwide. Tips on the tree are
70 annotated with circles and colored based on their locations; d) The inset tree on the right represent a Maximum Clade Credibility tree inferred
71 using a smaller dataset (n=111) which included all novel genomes from Ethiopia. Each branch is colored according to the legend on the left;
72 Ethiopian sequences are marked with a black circle. Support for branching structure is shown by posterior probability values at key nodes; e)
73 Representation of the spatiotemporal reconstruction of the spread of DENV3-III Major lineage B.

74

75 The sequencing procedure yielded an average coverage of 89%, ranging from 73.8% to 96.9%
76 (**Figure 1a**). This allowed for the identification of the DENV-3, genotype III, major lineage B,
77 following the recent release of the DENV classification system (11). Genome sequences were
78 obtained from all three districts of the Afar region: Mille, Logia, and Gewane (**Figure 1b**).

79 To understand the phylogenetic history of DENV-3, genotype III, we combined our recently
80 sequenced samples (n=7) from 2023 with a global set of reference samples. Our analysis
81 revealed that the new genomes cluster together within the major lineage B and that three
82 independent introduction events have occurred in Ethiopia over time (**Figure 1c**).

83 We then investigated the spatial-temporal dynamics of the Ethiopian DENV-3, genotype III, in
84 more detail using a smaller dataset (n=111) derived from the major lineage B, which has an
85 Asian origin (**Figure 1d**). Since 2015, this lineage has spread multiple times into Africa, the
86 Caribbean, and subsequently to North and South America, where it was recently described as
87 a re-emerging variant circulating in the region (**Figure 1e**) (12). Within the Ethiopian
88 sequences, we identified three distinct clades. Clade I dates back to early February 2021 (95%
89 Highest Posterior Density -HPD: April 2019 to February 2022) and includes Ethiopian strains
90 that cluster monophyletically with a genome sequence isolated in Rome, Italy, in 2023.
91 Although genetic data alone cannot provide evidence of transmission direction and potential
92 cryptic transmission must be considered due to the paucity of genomes from other locations,
93 our analyses indicate strong clustering support for the Ethiopian sequence with the one
94 recovered in Italy (posterior probability support = 1.0). Clade II, dating back to late June 2019
95 (95% HPD: January to October 2019), comprises two newly identified Ethiopian strains that
96 cluster with a strain isolated in Asia, suggesting a potential introduction from Asia to Ethiopia.
97 Clade III, dating back to July 2022 (95% HPD: April 2021 to October 2022), consists solely of
98 sequences from Ethiopia and shows a clear Asian origin. Given the limited sequences from
99 other locations and the low number of genomes from Ethiopia, this clade might represent
100 persistent local circulation within the country. Together these findings highlight the dynamic
101 nature of DENV-3 transmission and the complex epidemiological patterns in the country.

102 Conclusions

103 This study underscores the dynamic and complex nature of DENV-3 transmission within
104 Ethiopia. The introduction of at least three independent DENV-3 lineages into the Afar region,
105 as indicated by genomic evidence, highlights a significant epidemiological pattern. These
106 introductions have connections with distinct global regions including Asia and Europe,
107 particularly Italy, suggesting international travel and movement as potential vectors for disease
108 spread. Temporal and phylogenetic analyses reveal that while some of the identified strains
109 suggest recent introductions, others indicate more established, ongoing local transmission
110 within the country.

111 These findings are critical for the Ethiopian public health response, emphasizing the need for
112 robust surveillance systems that incorporate genomic epidemiology to track virus evolution
113 and spread effectively. Such efforts are essential not only for timely and targeted dengue control
114 measures but also for preparing for potential outbreaks of other imported viral diseases. This
115 study also reinforces the importance of international collaboration in genomic surveillance to
116 better understand and mitigate the spread of infectious diseases globally.

117 Additionally, this study produced near-complete genomes from the Afar region for the first-
118 time using Oxford Nanopore sequencing technology. This approach could be implemented in
119 Ethiopia and other African countries to enhance genomic surveillance and management of
120 DENV transmission in the region.

121

122 This work was supported, in whole or in part, by the Bill & Melinda Gates Foundation [Grants
123 No. INV-034,799 and INV-064464]. Under the grant conditions of the Foundation, a Creative
124 Commons Attribution 4.0 Generic License has already been assigned to the Author Accepted
125 Manuscript version that might arise from this submission. Other sources of funding include the
126 ICGEB CRP to Ethiopia (CRP/ETH21-01) and PNRR "GENESIS" - COC-1-2023-UNIPV -
127 ID S1.P0002 (INF-ACT).

128 The content and findings reported in this work are the sole responsibility of the researcher(s)
129 involved and do not necessarily reflect the official positions or sentiments of the funding
130 agencies that supported this project.

131 About the Author

132 Feleke Mekonnen is a PhD student at Bahir Dar University, Ethiopia. His research interests
133 include viral and bacterial infections. Currently, he is a visiting researcher at the Molecular
134 Virology Laboratory, ICGEB, Trieste, Italy.

135

136 References

- 137 1. Woyessa A, Tsegaye M, Kassa W, Kifle E, Wondabeku M, Girmay A, et al. The first
138 acute febrile illness investigation associated with dengue fever in Ethiopia, 2013: A
139 descriptive analysis. *Ethiopian Journal of Health Development*. 2014 Jul;28.
- 140 2. Eshetu D, Shimelis T, Nigussie E, Shumie G, Chali W, Yeshitela B, et al. Seropositivity
141 to dengue and associated risk factors among non-malarias acute febrile patients in Arba
142 Minch districts, southern Ethiopia. *BMC Infect Dis*. 2020 Aug 31;20(1):639.
- 143 3. Mekuriaw W, Kinde S, Kindu B, Mulualem Y, Hailu G, Gebresilassie A, et al.
144 Epidemiological, Entomological, and Climatological Investigation of the 2019 Dengue
145 Fever Outbreak in Gewane District, Afar Region, North-East Ethiopia. *Insects*. 2022
146 Nov 18;13(11).
- 147 4. Gutu MA, Bekele A, Seid Y, Mohammed Y, Gemechu F, Woyessa AB, et al. Another
148 dengue fever outbreak in Eastern Ethiopia-An emerging public health threat. *PLoS Negl
149 Trop Dis*. 2021 Jan;15(1):e0008992.
- 150 5. Sisay C, Waldetensai A, Seyoum M, Tayachew A, Wossen M, Keneni D, et al. Detection
151 of serotype 1-Dengue fever outbreak in Dire Dawa city, Eastern Ethiopia. *Ethiopian
152 Journal of Public Health and Nutrition (EJPHN)* [Internet]. 2022 Jan 27;5(1):49–54.
153 Available from: <https://ejphn.ephi.gov.et/index.php/ejphn/article/view/72>
- 154 6. Sisay C, Tadesse A, Workie F, Yizengaw A, Ali A, Yusuf J, et al. Description of Serotype
155 3 Dengue Fever Virus: Clinical, Surveillance and Geographical Expansion in the
156 Northeastern Ethiopia, 2023. *Science Journal of Public Health*. 2023 Aug 17;
- 157 7. Chien LJ, Liao TL, Shu PY, Huang JH, Gubler DJ, Chang GJJ. Development of real-
158 time reverse transcriptase PCR assays to detect and serotype dengue viruses. *J Clin
159 Microbiol*. 2006 Apr;44(4):1295–304.
- 160 8. Fonseca V, Libin PJK, Theys K, Faria NR, Nunes MRT, Restovic MI, et al. A
161 computational method for the identification of Dengue, Zika and Chikungunya virus
162 species and genotypes. *PLoS Negl Trop Dis*. 2019 May;13(5):e0007231.
- 163 9. Miguel I, Feliz EP, Agramonte R, Martinez P V, Vergara C, Imbert Y, et al. North-south
164 pathways, emerging variants, and high climate suitability characterize the recent spread
165 of dengue virus serotypes 2 and 3 in the Dominican Republic. *medRxiv*. 2024 Feb 15;
- 166 10. Quick J, Lansdowne L. ARTIC SARS-CoV-2 sequencing protocol v4 (LSK114) v2.
167 2024.
- 168 11. Hill V, Cleemput S, Fonseca V, Tegally H, Brito AF, Gifford R, et al. A new lineage
169 nomenclature to aid genomic surveillance of dengue virus. *medRxiv*. 2024 May 17;
- 170 12. Miguel I, Feliz EP, Agramonte R, Martinez P V, Vergara C, Imbert Y, et al. North-south
171 pathways, emerging variants, and high climate suitability characterize the recent spread
172 of dengue virus serotypes 2 and 3 in the Dominican Republic. *medRxiv*. 2024 Feb 15;

Table 1: Sociodemographic Characteristics of Dengue cases in Afar Region, Ethiopia. June-October, 2023.

Variables	Socioeconomic Status of AFI cases			COR (95%CI)	P-value
	Dengue IgM				
	Positive N (%)	Negative N (%)			
Gender					
Male	102(32.4)	213(67.6)	1(0.643_1.928)	0.7	
Female	24(34.8)	45(65.2)	0		
Age(yr)					
(6-15)	3(2.4)	7(2.7)	0		
(16-45)	50(39.7)	103(39.9)	0.85(0.214-3.388)	0.82	
(>46)	73(57.9)	148(57.4)	0.91(0.226-3.668)	1	
Residence					
Urban	56(37.7)	101(64.3)	1.2(0.745-1.972)	0.44	
Semi-Urban	27(30)	63(70)	1.3(0.741-2.251)	0.37	
Rural	43(31.4)	94(68.6)	0		
Marital Status					
Single	84(31.5)	183(68.5)	0.8(0.519-1.295)	0.39	
Married	42(35.9)	75(64.1)	0		
Occupation					
Governmental	3(37.5)	5(62.5)	0		
Pastoralist	57(32.8)	117(67.2)	1.2(0.284-5.335)	0.78	
Unemployed	34(39.5)	52(60.5)	1.2(0.262-5.836)	0.79	
House wife	16(32.7)	33(67.3)	0.92(0.206-4.093)	0.91	
Merchant	3(33.3)	6(66.7)	1.2(0.164-8.799)	0.86	
Others	13(22.4)	45(77.6)	2(0.437-9.871)	0.36	
Health Facility					
Logia health center	89(40.6)	130(59.4)	2.2(0.963-5.139)	0.61	
Mille health center	29(22.1)	102(77.9)	0.9(0.378-2.258)	0.86	
Gewane health center	8(23.5)	26(76.5)			

0 = reference group, * = statistically significant (p -value < 0.05), COR (95%CI) = crudes odds ratio at 95% confidence interval

Table 2: Clinical Characteristics of Dengue patients in Afar region, Ethiopia, June-October 2023.

Variables	Dengue IgM		COR (95%CI)	P-value
	Positive, N (%)	Negative N (%)		
Fever				
Yes	121(32.9)	247(67.1)	1(0.366-3.17)	0.9
No	5(31.3)	11(68.8)		
Severe Headache				
Yes	121(32.7)	249(67.3)	0.8(0.287- 2.67)	0.8
No	5(35.7)	9(64.3)		
Eye pain				
Yes	62(29.5)	148(70.5)	21(8.145-55.770)	0.0001
No	64(36.8)	110(63.2)		
Muscle and Joint Pain				
Yes	99(33)	201(67)	1(0.6199-1.744)	0.8
No	27(32.1)	57(67.9)		
Nausea				
Yes	77(35.6)	139(64.4)	1.3(0.872-2.076)	0.2
No	49(29.2)	119(70.8)		
Swollen Gland				
Yes	3(27.3)	8(72.7)	0.8(0.199 to 2.924)	0.7
No	123(33)	250(67)		
Rash				
Yes	2(33.3)	4(66.7)	1(0.185 to 5.668)	0.978
No	124(32.8)	254(66.1)		
Respiratory Distress				
Yes	17(37.8)	28(62.2)	1.3(0.673 to 2.440)	0.45
No	109(32.2)	230(67.8)		
Bleeding gum				
Yes	2(28.6)	5(71.4)	0.8(0.156 to 4.266)	0.81
No	124(32.9)	253(67.1)		
Organ Impairment				
Yes	3(37.5)	5(62.5)	1.2(0.290-5.248)	0.77
No	123(32.7)	253(67.3)		
Severe Abdominal Pain				
Yes	43(36.4)	75(63.6)	1.3(0.801-1.994)	0.31

Vomiting	No	83(31.2)	183(68.8)		
	Yes	50(40)	75(60)	1.6(1.027-2.509)	0.038
Fatigue	No	76(29.3)	183(70.7)		
	Yes	61(31.1)	135(68.9)	0.9(0.558-1.310)	0.47
	No	65(34.6)	123(65.4)		

*0 = reference group, * = statistically significant (p-value < 0.05), COR (95%CI) = crudes odds ratio at 95% confidence interval*

Table 3: Primers used for DENV-3 Sequencing

Primer Name	Sequence (5'-3')	Pool
DENV3_1_LEFT	TCAATATGCTGAAACGCGTGAGA	1
DENV3_1_RIGHT	GCCTCGGTCTTCTGAAGCTCTA	1
DENV3_2_LEFT	GGGAGTAGGAAACAGAGATTTTGTGG	2
DENV3_2_RIGHT	GAGTATTGTCCRTGCTGCGTT	2
DENV3_3_LEFT	ACCAATAGAGGGAAAAGTGGTGC	1
DENV3_3_RIGHT	TGGCCTCGAACATCTTCCCAAT	1
DENV3_4_LEFT	GCTGAACCTCCTTTTGGGGAAA	2
DENV3_4_RIGHT	TTCCACCTCCCACACATTCCAT	2
DENV3_5_LEFT	GGCAAAAATAGTGACAGCTGAAACA	1
DENV3_5_RIGHT	TCTCCATGTTATTTGCCCTGAGAGA	1
DENV3_6_LEFT	AGGTGGACAACCTCACAATGGG	2
DENV3_6_RIGHT	CTCAGCCTCTTCCCTCCCATGTT	2
DENV3_7_LEFT	GCCAGTCTTCRAGCATGAGGAA	1
DENV3_7_RIGHT	TTCCCAGGCTCTACGGCAATAA	1
DENV3_8_LEFT	AAAGACTGGAACCAAACCTGGGC	2
DENV3_8_RIGHT	TGCCTGAATTCCATGAGCGTTC	2
DENV3_9_LEFT	GCAACAAAATCTGAACACACAGGA	1
DENV3_9_RIGHT	CCCTCCTCATGAGTTCCACGAA	1
DENV3_10_LEFT	AGACCATGCTCACTGGACAGAA	2
DENV3_10_RIGHT	TATGCGAGTTGGTTGTCTTGGG	2
DENV3_11_LEFT	GGAAAGACTTCAATAGGACTCATTTGTG	1
DENV3_11_RIGHT	CAGGTGATCCTTCCCAGAGTGT	1
DENV3_12_LEFT	GTGGATGGGATAATGACAATAGACCT	2
DENV3_12_RIGHT	GGTGCTCAATCACAGTTGGCAT	2
DENV3_13_LEFT	AGTGGAAGAAAGCAGAACTATAAGAGT	1
DENV3_13_RIGHT	TGGAGTTCACGTTCTCTGTCCA	1
DENV3_14_LEFT	GGAGAACCCTGGGAAGGAACAA	2
DENV3_14_RIGHT	ATGGCTGCCATTGAGGTATGTC	2
DENV3_15_LEFT	TGGACATCATATCTAGGAAAGACCAAAG	1
DENV3_15_RIGHT	AGGTTGCTCTGGAAGTGAGACC	1

PROTOCOL: Brief ONT sequencing protocol for DENV-3¹

Briefly 12 µl of RNA was reversely transcribed using 3 µl of Luna Script RT Super-Mix Kit (New England Biolabs, U.S.) at a thermocycler following temperature cycles of 25 °C for 2 min, 55 °C for 10 min, and 95 °C for 1 min, followed by DENV3-specific multiplex PCR in 2 pools by using Q5 Hot Start High-Fidelity 2x Master Mix (New England Biolabs, U.S.) with the cycling conditions of 98 °C for 30 seconds followed by 40 cycles of 95 °C for 15 seconds, 50 °C for 30 seconds, 72 °C for 60 seconds & final extension of 72 °C for 2 minutes. The resulting PCR products were quantified by the Qubit dsDNA High Sensitivity assay on a Qubit 4 fluorometer (Thermo Fisher Scientific, USA). The products were pooled in 1:1 ratio and purified by SPRI PCR Clean Dx beads (Aline biosciences, U.S.) which were further subjected to end-preparation by NEBNext® Ultra™ II End Repair/dA-Tailing Module (New England Biolabs, U.S.) and barcoded by Native Barcode Expansion Kit-NBD196 (Oxford Nanopore Technologies, UK). The barcoded samples were consolidated and cleaned by SPRI beads as described above followed by AMII adaptor ligation by NEBNext® Quick Ligation Module (New England Biolabs, U.S.). The final library was SPRI cleaned up, quantified and loaded into R9.4.1 flow Cell using the Ligation Sequencing Kit-LSK110 (Oxford Nanopore Technologies, UK). The sequencing data were collected for 16 hours, and the raw reads were base called and de-multiplexed in MinION Mk1C in-built tools in Minknow v 22. The resulting FASTQ files were used to generate consensus sequences by using de novo assembly in Genome Detective web tool (<https://www.genomedetective.com/>).

GenBank accession numbers for the nucleotide sequence(s):

SUB14602032 DENV_Ethiopia-54 PQ014884

SUB14602032 DENV_Ethiopia-51 PQ014885

SUB14602032 DENV_Ethiopia-52 PQ014886

SUB14602032 DENV_Ethiopia-53 PQ014887

SUB14602032 DENV_Ethiopia-55 PQ014888

SUB14602032 DENV_Ethiopia-49 PQ014889

SUB14602032 DENV_Ethiopia-58 PQ014890

¹A detailed version of this protocol is available on request.

Phylogenetic and Phylogeographic Analysis Method

Sequence alignment was done using MAFFT and edited with AliView. A preliminary phylogenetic tree was built using IQ-TREE 2 with the GTR+G4 model (13) signal was evaluated with TempEst, and outliers were removed before creating a time-scaled tree using TreeTime. Phylogenetic relationships were inferred using a smaller dataset which included the Ethiopian strains (n=111) using BEAST v1.10.4 with a relaxed lognormal clock, skygrid population size, and GTR model. Phylogeographic analysis considered six locations: Asia, Africa, North America, Europe, South America, and the Caribbean. The analysis used an empirical distribution of 1000 trees, running the MCMC chain for 100 million iterations, sampling every 1000. Maximum clade credibility (MCC) trees were summarized using TreeAnnotator v1.10.4 and visualized with the ggtree package in R. Geographic visualization was performed using SpreaD3.